TR2021017805A2 - A VITAMIN D CONTAINING DRUG FOR USE AS A LOCAL PAIN RELIEF TO TREAT JOINT PAIN - Google Patents
A VITAMIN D CONTAINING DRUG FOR USE AS A LOCAL PAIN RELIEF TO TREAT JOINT PAINInfo
- Publication number
- TR2021017805A2 TR2021017805A2 TR2021/017805A TR2021017805A TR2021017805A2 TR 2021017805 A2 TR2021017805 A2 TR 2021017805A2 TR 2021/017805 A TR2021/017805 A TR 2021/017805A TR 2021017805 A TR2021017805 A TR 2021017805A TR 2021017805 A2 TR2021017805 A2 TR 2021017805A2
- Authority
- TR
- Turkey
- Prior art keywords
- vitamin
- drug
- pain
- joint
- sodium
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 44
- 208000006820 Arthralgia Diseases 0.000 title claims abstract description 16
- 229940079593 drug Drugs 0.000 title claims description 37
- 208000002193 Pain Diseases 0.000 title description 11
- 230000036407 pain Effects 0.000 title description 11
- 229940088594 vitamin Drugs 0.000 title description 4
- 229930003231 vitamin Natural products 0.000 title description 4
- 235000013343 vitamin Nutrition 0.000 title description 4
- 239000011782 vitamin Substances 0.000 title description 4
- 150000003722 vitamin derivatives Chemical class 0.000 title description 4
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 33
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 33
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 33
- 239000011710 vitamin D Substances 0.000 claims abstract description 33
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 33
- 229940046008 vitamin d Drugs 0.000 claims abstract description 33
- 238000002347 injection Methods 0.000 claims abstract description 7
- 239000007924 injection Substances 0.000 claims abstract description 7
- 229940124641 pain reliever Drugs 0.000 claims abstract description 7
- 210000002966 serum Anatomy 0.000 claims description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 6
- 239000003246 corticosteroid Substances 0.000 claims description 5
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 4
- 235000019800 disodium phosphate Nutrition 0.000 claims description 4
- 239000003094 microcapsule Substances 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 235000002639 sodium chloride Nutrition 0.000 claims description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
- 239000003193 general anesthetic agent Substances 0.000 claims description 3
- 229920002674 hyaluronan Polymers 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- 206010008685 Chondritis Diseases 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 239000002199 base oil Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 claims description 2
- 235000019797 dipotassium phosphate Nutrition 0.000 claims description 2
- KDQPSPMLNJTZAL-UHFFFAOYSA-L disodium hydrogenphosphate dihydrate Chemical compound O.O.[Na+].[Na+].OP([O-])([O-])=O KDQPSPMLNJTZAL-UHFFFAOYSA-L 0.000 claims description 2
- 239000003589 local anesthetic agent Substances 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- BTRXYXNWHKNMAB-UHFFFAOYSA-N phosphoric acid;dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.OP(O)(O)=O BTRXYXNWHKNMAB-UHFFFAOYSA-N 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000001488 sodium phosphate Substances 0.000 claims description 2
- 229940074404 sodium succinate Drugs 0.000 claims description 2
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 claims description 2
- 230000000694 effects Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010047626 Vitamin D Deficiency Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 210000000929 nociceptor Anatomy 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Bu buluş, parenteral yolla, özellikle enjeksiyon yoluyla eklem içine uygulanması özelliğindeki, eklem ağrısı tedavisinde lokal ağrı kesici olarak kullanılması için D vitamini içeren bir ilaç ile ilgilidir.The present invention relates to a medicament containing vitamin D for use as a local pain reliever in the treatment of joint pain, which is administered parenterally, particularly by injection, into the joint.
Description
TARIFNAME EKLEM AGRISI TEDAVISINDE BIR LOKAL AGRI KESICI OLARAK KULLANILMASI IÇIN D VITAMINI IÇEREN BIR ILAÇ Teknik Alan Bu bulus, parenteral yolla, özellikle enjeksiyon yoluyla eklem içine uygulanmasi özelligindeki, eklem agrisi tedavisinde lokal agri kesici olarak kullanilmasi için D vitamini içeren bir ilaç ile ilgilidir. DESCRIPTION AS A LOCAL PAIN RELIEF IN THE TREATMENT OF JOINT PAIN A MEDICINE CONTAINING VITAMIN D FOR USING Technical Area This invention is intended for parenteral administration, particularly intra-articular administration by injection. D for use as a local pain reliever in the treatment of joint pain, It relates to a medicine containing vitamin B.
Bulusun Öncesi Eklem agrisi, toplumda her bes kisiden birinde görülebilecek siklikta bir rahatsizliktir. Eklem agrisi çok çesitli nedenlere bagli olabilir ancak agri genellikle yaralanmanin veya artritinin bir sonucudur. Yaslilarda genellikle osteoartrit baslangicinin bir sonucu olarak giderek kötülesen eklem agri görülebilir. Agrilar bir veya birden fazla eklem bölgesinde görülebilir. Eklem agrilari çogunlukla kronik agrilar olup hasta yasam kalitesini ve hareketini önemli ölçüde düsürür. Before the Invention Joint pain is a frequent problem that can be seen in one out of every five people in the society. is inconvenience. Joint pain can be due to a variety of causes, but pain is usually is a result of injury or arthritis. Osteoarthritis in the elderly As a result of its onset, progressively worsening joint pain may occur. Agrilar It can be seen in one or more joint areas. Joint pain is often They are chronic pains and significantly reduce the patient's quality of life and movement.
Teknigin öncesinde eklem agrisinin tedavisi enteral yolla, çogunlukla oral yolla alinan agri kesiciler ile gerçeklestirilir. Ancak bu agri kesiciler kronik eklem agrilarina uzun süreli cevap veremezler. Alternatif olarak agrili ekleme lokal anesteziklerin ve kortikosteroidlerin eklem sivisina enjekte edilmesi, PRP, Kök hücre uygulamasi, hyalüronik asit enjeksiyonlari gibi agri tedavi yöntemleri bulunmaktadir. Ancak bu yöntemlerin eklem agrisi tedavisindeki etkinligi ve etkinlik süreleri sinirlidir. Before the technique, the treatment of joint pain was administered enterally, mostly orally. It is performed with the pain relievers taken. However, these pain relievers are chronic joint they cannot respond to their pain for a long time. Alternatively, the painful insertion is local. injection of anesthetics and corticosteroids into joint fluid, PRP, Root pain treatment methods such as cell application, hyaluronic acid injections are available. However, the effectiveness of these methods in the treatment of joint pain and Activity times are limited.
Yukarida anlatilan problemlerden ötürü eklem agrisinin etkin tedavisi için bir ilaca teknikte ihtiyaç duyulmaktadir. For the effective treatment of joint pain due to the problems described above, a drug is needed. technique is needed.
Bulusun Ayrintili Açiklamasi Bulus eklem agrisi tedavisinde bir lokal agri kesici olarak kullanilmasi için D Vitamini içeren bir ilaç olup özelligi ilacin parenteral yolla eklem içine uygulanmasidir. Detailed Description of the Invention The invention is D for use as a local pain reliever in the treatment of joint pain. It is a drug containing vitamin and its feature is that the drug is injected into the joint by parenteral route. is the implementation.
D vitamini insan sagligi için hayati öneme sahiptir. Günese maruz kaldigimizda Vücudumuz tarafindan üretilebilmesinden dolayi D Vitamini günes Vitamini olarak da bilinir. D vitaminin en önemli islevi bagisiklik sistemini güçlendirmesidir, kalsiyum ve fosfor emilimini düzenlemesidir. D vitamini eksikligi fiziksel ve zihinsen problemleri beraberinde getirebilir. Eksikligin fiziksel semptomlari eklemlerde, özellikle dizlerde, bacaklarda ve kalçada ortaya çikan romatoid artrit agri biçiminde olabilir. Dolayisiyla D vitamini takviyeleri yardimiyla D vitamini eksikliginin giderilmesi kas ve iskelet sistemi sagligina katkida bulunabilmektedir. Vitamin D is vital for human health. when we are exposed to the sun Vitamin D is called a sun vitamin because it can be produced by our body. also known. The most important function of vitamin D is to strengthen the immune system, regulates the absorption of calcium and phosphorus. Vitamin D deficiency and physical It can bring mental problems. physical symptoms of deficiency rheumatoid arthritis that occurs in the joints, especially the knees, legs, and hips It may be in the form of a grimace. Therefore, with the help of vitamin D supplements, vitamin D Elimination of its deficiency can contribute to the health of the musculoskeletal system.
D vitamini takviyeleri oral yolla ya da intramüsküler enjeksiyon yoluyla alinabilir. Vitamin D supplements can be taken orally or by intramuscular injection.
Kesin kanitlar olmasa da enflamasyon kaynakli eklem agrilarinin olusmamasina katki saglayabilecegi düsünülmektedir. Although there is no conclusive evidence, joint pain caused by inflammation does not occur. It is thought that it can contribute.
Bilinen teknigin öncesinde D vitaminin eklem içine parenteral yolla uygulanarak eklem agrisi tedavisinde bir lokal agri kesici ilaç olarak kullanilmasina dair bir bilgi yer almamaktadir. Basvuru konusu bulustaki D vitamini içeren ilacin farkli fonksiyonu [lokal agri kesici olmasi] ve uygulama yolu (route of administration) use] gerçeklestirilmistir. Teknigin öncesinde yer alan D vitamin takviyeleri alimi sonrasi D vitamini noksanliginin giderilmesi vasitasiyla gerçeklestirilen etkiler ile bulus konusu D vitamini içeren ilacin uygulama yolu vasitaliyla gerçeklestirilmis lokal agri kesici etkiler birbiri ile karistirilmamalidir. Prior to the known technique, parenteral administration of vitamin D into the joint Information on its use as a local pain reliever in the treatment of joint pain is not included. The subject of the application is different from the drug containing vitamin D in the invention. function [local pain relief] and route of administration use] has been implemented. Purchase of vitamin D supplements prior to the technique with the effects realized through the elimination of vitamin D deficiency after The subject of the invention was carried out through the application route of the drug containing vitamin D. local pain relief effects should not be confused with each other.
Bulus konusu ilacin parenteral yolla eklem içine uygulanmasi sonrasi ilaç eklem içeresindeki agri reseptörlerine baglanarak agrinin kesilmesini saglar. Bununla birlikte eklemde lokal antienflamatuar etki olusturarak eklemde yer alan enflamasyonu tedavi eder. After parenteral administration of the subject of the invention into the joint, the drug is injected into the joint. It provides pain relief by binding to the pain receptors in it. With this together, it creates a local anti-inflammatory effect in the joint. treats inflammation.
Bulusun tercih edilen bir uygulamasinda parenteral yol enjeksiyon biçimindedir. In a preferred embodiment of the invention, the parenteral route is in the form of injection.
Bu uygulamada ilaç enjeksiyon yolu ile eklem içine uygulanir. In this application, the drug is administered into the joint by injection.
Bulusun uygulamalarinda D Vitaminin çesitli türevleri kullanilabilir. Various derivatives of Vitamin D can be used in applications of the invention.
Bulusun bir uygulamasinda ilaç D vitamini tasiyici bir yag içerir. In one embodiment of the invention, the drug comprises a vitamin D carrier oil.
Bulusun bir uygulamasinda ilaç mikrokapsüller içerir. Bu uygulamada ilacin en az bir bölümü en az D vitamini içeren bir mikrokapsüller biçimindedir. In one embodiment of the invention, the drug includes microcapsules. In this application, the drug is at least part of it is in the form of microcapsules containing at least vitamin D.
Bulusun bir uygulamasinda ilaç platelet/trombosit hücrelerinden zengin kan [PRP (Platelet Rich Plasma)], kök hücre, hyalüronik asit, omega 3, kortikosteroid, anestezik bir madde, polipetid (Örnegin oligopeptid, nonapeptid, oktapeptid, hepapeptid, dekapeptid), lokal anestezik, kortikosteroid, sodyum klorit, disodyum fosfat, potasyum hidrojen fosfat, sodyum klorür, sodyum hidrojen fosfat dihidrat, dibazik sodyum, fosfat dodekahidrat, fosfat tamponlu tuz, sodyum monohidrojen fosfat, sodyum hidrojen fosfat, sodyum süksinat, manitol ve/Veya kondritin sülfat içerir. Bulusun uygulamalarinda ilaç bir karisim veya bir bilesik biçiminde olabilir. In one embodiment of the invention, the drug is platelet/platelet-rich blood [PRP]. (Platelet Rich Plasma)], stem cell, hyaluronic acid, omega 3, corticosteroid, an anesthetic agent, polypeptide (For example, oligopeptide, nonapeptide, octapeptide, hepapeptide, decapeptide), local anesthetic, corticosteroid, sodium chloride, disodium phosphate, potassium hydrogen phosphate, sodium chloride, sodium hydrogen phosphate dihydrate, dibasic sodium, phosphate dodecahydrate, phosphate buffered salt, sodium monohydrogen phosphate, sodium hydrogen phosphate, sodium succinate, mannitol and/or chondritis sulfate includes. In embodiments of the invention, the drug may be in the form of a mixture or a compound.
Bu karsim veya bilesik ilacin içerecegi mikrokapsüller içerisinde yer alabilir. This mixture or compound may be included in the microcapsules that the drug will contain.
Bulusun bir uygulamasinda ilaç en fazla 600000 ünite D vitamini içerir [ünite: IU = international units]. Bulusun bir uygulamasindaki dozaj rejiminde tek seferde en fazla 600000 ünite D vitamini içeren ilaç parenteral yolla eklem içine uygulanir. In one embodiment of the invention, the drug contains up to 600000 units of vitamin D [unit: IU = international units]. In the dosage regimen in one embodiment of the invention, the most The drug containing more than 600000 units of vitamin D is administered parenterally into the joint.
Birden fazla ekleme uygulama yapilacak ise 600000 ünite D vitamini içeren ilaç eklemler arasinda paylastirilmasi seklinde uygulama yapilabilir. Buradaki sinirlama uygulama sonrasi Vücuttaki serum D vitamini seviyesinin artmasidir. Yetiskin bir insandaki serum D Vitamini toksik düzeyi 150 ng/ml üzeridir. Bazi otoritelerce bu deger 240 ng/ml üzeri olarak belirtilmistir. Serum D vitamini toksik düzeyi asilmadigi sürece uygulama oldukça güvenlidir. 600000 ünite D vitamini içeren ilacin uygulamasi sonrasi ortalama bir insandaki serum D vitamini düzeyi yaklasik 20730 ng/ml düzeyinde artis gösterir. If more than one joint is to be applied, a drug containing 600000 units of vitamin D It can be applied in the form of sharing between the joints. the anger here It is the increase of serum vitamin D level in the body after the application. an adult The toxic level of serum Vitamin D in humans is above 150 ng/ml. According to some authorities, this The value is stated as over 240 ng/ml. Serum vitamin D toxic level As long as it is not hung, the application is quite safe. Contains 600000 units of vitamin D After administration of the drug, the serum vitamin D level in an average person is approximately It increases at the level of 20730 ng/ml.
Ilaç dozaj rejimi hastanin serum D vitamini düzeyi ölçülerek belirlenir veya hasta hikayesi dinlenerek serum D vitamini düzeyi öngörülür. Ardindan hastanin serum D vitamini düzeyini toksik düzeye ulastirmayacak oranlarda ilaç dozaj rejimi belirlenir ve ilaç eklem içine uygulanir. Serum D vitamini düzeyi 100 ng/ml üzerinde olan hastalara ilacin uygulanmasinda imtina gösterilmelidir. Bulusun bir uygulamasi 90 ng/ml”den az serum D vitamini düzeyine sahip hastalara uygulanmasini içerir. The drug dosage regimen is determined by measuring the patient's serum vitamin D level, or the patient's The serum vitamin D level is predicted by listening to the history. Then the patient's serum Drug dosage regimen at rates that will not reach the toxic level of vitamin D determined and the drug is administered into the joint. Serum vitamin D level 100 ng/ml Administration of the drug should be avoided in patients with find one administration to patients with serum vitamin D levels less than 90 ng/ml includes its implementation.
Ilacin uygulamasi sonrasi yüksek seviye kalsiyum alimi yapilmamalidir. Bununla birlikte magnezyum aliminin tedaviye olumlu katki sagladigi gözlemlenmistir. After the application of the drug, high levels of calcium intake should not be done. With this It has been observed that magnesium intake together with it contributes positively to the treatment.
Uygulama sonrasi ilk 24 saatte eklemde hafif bir enflamasyon gözlemlenebilir. A slight inflammation can be observed in the joint in the first 24 hours after the application.
Bazen enflamasyon nadiren 48 saat kadar sürebilir. Gözlemlenen bu enflamasyonun olumsuz etkilerinin azaltilmasi için bahsedilen süreler boyunca antienflamatuar-analjezik kullanilabilir. Bu kullanima alternatif veya ek olarak uygulama yapilmis ekleme lokal soguk baski yapilabilir. Bu sürenin ardindan ilacin agri kesici etkisi ve antientlamatuar etkisi baslar. Ilacin azami agri kesici etkisi uygulamayi takip eden ikinci hafta sonrasinda gözlemlenir. Ilaç agri kesici etkisini 3-12 ay süre boyunca sürdürebilir. Sometimes the inflammation can last up to 48 hours, rarely. This is observed during the aforementioned periods to reduce the negative effects of inflammation. Anti-inflammatory-analgesics can be used. As an alternative or addition to this use Local cold pressure can be applied to the applied joint. After this period, the drug pain relief effect and anti-inflammatory effect begins. Maximum pain relief effect of the drug observed after the second week following the application. The pain relief effect of the drug It can last for 3-12 months.
Bulusun bir uygulamasi ilacin en az 3 ay en fazla 12 ay araliklarla eklem içine uygulanmasini içerir. Ilacin bir uygulama rejiminde ilaç her 3-12 ay arasindaki bir zaman araliklari ile uygulanir. Hastanin serum D vitamini düzeyinin toksik düzelere ulasmayacagina emin olunmasi kosulu ile ilacin istenilen dozaj rejiininde (istenilen ünite D vitamini içeriginde) ve siklikta uygulanmasi mümkündür. In an application of the invention, the drug is injected into the joint at intervals of at least 3 months and at most 12 months. includes its implementation. In an administration regimen of the drug, the drug should be administered every 3-12 months. applied with time intervals. Toxic recovery of the patient's serum vitamin D level In the desired dosage regimen of the drug (desired unit of vitamin D) and it is possible to apply it frequently.
Bulus konusu ilaç özellikle artroskopi sonrasi, eklem ameliyati sonrasi ve romatizmal rahatsizlik kaynakli eklem agrilarinin tedavisinde oldukça etkilidir. The subject of the invention is the drug especially after arthroscopy, after joint surgery and It is very effective in the treatment of joint pain caused by rheumatic discomfort.
Bulus konusu ilacin seçilmis dozlarini içeren hazir enjektör biçimindeki uygulamalarinin gerçeklestirilmesi mümkündür. In the form of a ready-to-use syringe containing selected doses of the subject drug of the invention. applications are possible.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2021/017805A TR2021017805A2 (en) | 2021-11-16 | 2021-11-16 | A VITAMIN D CONTAINING DRUG FOR USE AS A LOCAL PAIN RELIEF TO TREAT JOINT PAIN |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2021/017805A TR2021017805A2 (en) | 2021-11-16 | 2021-11-16 | A VITAMIN D CONTAINING DRUG FOR USE AS A LOCAL PAIN RELIEF TO TREAT JOINT PAIN |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR2021017805A2 true TR2021017805A2 (en) | 2021-11-22 |
Family
ID=85113475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2021/017805A TR2021017805A2 (en) | 2021-11-16 | 2021-11-16 | A VITAMIN D CONTAINING DRUG FOR USE AS A LOCAL PAIN RELIEF TO TREAT JOINT PAIN |
Country Status (1)
| Country | Link |
|---|---|
| TR (1) | TR2021017805A2 (en) |
-
2021
- 2021-11-16 TR TR2021/017805A patent/TR2021017805A2/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| So et al. | A pilot study of IL-1 inhibition by anakinra in acute gout | |
| HRP20161221T1 (en) | Compositions for treating an arthritic condition | |
| US20130123319A1 (en) | Medthod of Treating a systemic inflammatory disorder and damaged internal tissues | |
| EP1677806B1 (en) | Methods for treating acute and overuse sprain and strain using hyaluronic acid | |
| KR20140025314A (en) | A combination composition | |
| Sucuoğlu et al. | The short-term effect of PRP on chronic pain in knee osteoarthritis | |
| AU2009304002B2 (en) | A medicinal product and treatment | |
| JP2019506397A5 (en) | ||
| Shallenberger et al. | Prolozone™–regenerating joints and eliminating pain | |
| Baum et al. | Treatment of psoriatic arthritis with 6‐mercaptopurine | |
| TR2021017805A2 (en) | A VITAMIN D CONTAINING DRUG FOR USE AS A LOCAL PAIN RELIEF TO TREAT JOINT PAIN | |
| US6172053B1 (en) | Injection viral treatment | |
| TR2021017802A2 (en) | A VITAMIN D CONTAINING DRUG FOR USE AS A LOCAL PAIN RELIEF | |
| Vamshi et al. | A prospective study of intra-articular injections of platelet rich plasma in early osteoarthritis knee joint | |
| CN1751739A (en) | Use of alpha-1 antitrypsin for the preparation of medicaments for the treatment of fibromyalgia | |
| JP2004514698A (en) | Method of treatment involving administration of substance P | |
| RU2476248C2 (en) | Method of treating rheumatoid arthritis | |
| JPWO2014050912A1 (en) | Liquid medicine dissolved with carbon dioxide and therapeutic method using the same | |
| Moder et al. | Effects of low-dose radon therapy applied under hyperthermic conditions (RnHT) on inflammatory and non-inflammatory degenerative disease conditions | |
| RU2709141C1 (en) | Method of treating rheumatoid arthritis | |
| RU2632621C1 (en) | Method for treating knee osteoarthrosis deformans | |
| UA135614U (en) | METHOD OF TREATMENT OF CHRONIC SIALODENITITES WITH EARLY MANIFESTATIONS OF SHEGREN'S SYNDROME | |
| Patil et al. | Role of Ayurveda in the management of Post-traumatic chronic inflammatory synovitis of knee joint-A Case Report | |
| Paice et al. | Pain Syndromes of Hematologic Malignancies | |
| Masiak et al. | THU0437 Illness perception and its correlates in patients with in anca-associated vasculitis–preliminary report |